MATINAS BIOPHARMA HOLDINGS, INC. Additional Paid in Capital, Common Stock
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Additional Paid in Capital, Common Stock of $215.83 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $215.83M.
- 2026-03-31: Additional Paid in Capital, Common Stock $215.73M.
- 2025-12-31: Additional Paid in Capital, Common Stock $215.62M.
- 2025-09-30: Additional Paid in Capital, Common Stock $215.33M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $215.83M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $215.73M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $215.62M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $215.33M 10-Q · filed 2025-11-10 |
| 2024-12-31 | $207.41M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |